Table 4.
Ongoing clinical trials using ICIs as adjuvant therapy for post-surgery NSCLC patients.
| Trial | Stage | Estimated Enrollment | Treatment Procedure | Primary Endpoint |
|---|---|---|---|---|
| ANVIL (NCT02595944) | Stages IB-IIIA | 903 | Surgery +/− chemotherapy → nivolumab vs. observation | DFS, OS |
| PEARLS (NCT02504372) |
Stages IB-IIIA | 1177 | Surgery +/− chemotherapy → pembrolizumab vs. placebo | DFS |
| IMpower010 (NCT02486718) |
Stages IB-IIIA | 1280 | Surgery +/− chemotherapy → atezolizumab vs. best supportive care | DFS |
| BR31 (NCT02273375) |
Stages IB-IIIA | 1360 | Surgery +/− chemotherapy → durvalumab vs. placebo | DFS |
Abbreviations: ICIs, immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; DFS, disease-free survival; OS, overall survival.